Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Dry Age-Related Macular Degeneration: early-phase trial registry

3 of 8 indexed Dry Age-Related Macular Degeneration trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

8 US clinical trials · 3 currently recruiting · #2,176 of 28,707 conditions by registered trial count

Dry Age-Related Macular Degeneration: 8 US clinical trials tracked, 3 recruiting.

Dry Age-Related Macular Degeneration is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is LumiThera, running 2 of these trials.

Enrollment posture brief

Registry condition dry-age-related-macular-degeneration

OPEN 3 | RECR 38% | LATE 0 | EARLY 4 | RANK #2176 | SPON 2

Volume-matched condition peers

Nearest open-share peer: Acute-graft-versus-host Disease (38% recruiting · 8 trials)

Activity, Motor75%Achalasia50%Dry Age-Related Macular (th…38%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%
Open-enrollment share among volume-matched conditions near Dry Age-Related Macular Degeneration

Dry Age-Related Macular Degeneration lists 3 open slots (38% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Dry Age-Related Macular Degeneration on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Dry Age-Related Macular Degeneration is recruiting below its size-band peers.

    3 of 8 indexed trials (37.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Dry Age-Related Macular Degeneration research.

    LumiThera accounts for 2 of 8 trials (25%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Most Dry Age-Related Macular Degeneration trials plan to enrol fewer than 100 people.

    Median target enrolment is 75 among the 8 trials that report a genuine target (sentinel values excluded). 7 of those (87.5%) plan for fewer than 100 participants.

  4. Dry Age-Related Macular Degeneration research is mostly interventional.

    7 interventional and 1 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 22

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 2

Top Sponsors

LumiThera 2 trials
i-Lumen Scientific 1 trials
Science Corporation 1 trials
Complement Therapeutics 1 trials
Regenerative Patch Technologies 1 trials
Luxa Biotechnology 1 trials
National Eye Institute (NEI) 1 trials

Named interventions

Most-linked intervention names on Dry Age-Related Macular Degeneration records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

i-Lumen(TM) AMD Sham Device
1 trials
i-Lumen(TM) AMD Device
1 trials
Valeda Sham treatment Device
1 trials
Valeda PBM treatment Device
1 trials
PRIMA Device
1 trials
Valeda Light Delivery System Device
1 trials
Surgical implantation of the CPCB-RPE1 implant Device
1 trials
RPESC-RPE-4W Biological
1 trials

US sites by state

Facility locations filed on Dry Age-Related Macular Degeneration trials. A trial with sites in several states counts in each.

California 7 trials
Texas 5 trials
Pennsylvania 4 trials
Maryland 4 trials
Florida 3 trials
Washington 2 trials
New York 2 trials
Illinois 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Dry Age-Related Macular Degeneration page

8 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 3 Dry Age-Related Macular Degeneration trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • LumiThera sponsors the most Dry Age-Related Macular Degeneration trials on record, review their full trial history before evaluating a specific study. See LumiThera's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Dry Age-Related Macular Degeneration condition card totals 8 registered trials; most-linked intervention i-Lumen(TM) AMD Sham; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.